These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 32386592)

  • 1. Monotherapy with a P2Y
    Chiarito M; Sanz-Sánchez J; Cannata F; Cao D; Sturla M; Panico C; Godino C; Regazzoli D; Reimers B; De Caterina R; Condorelli G; Ferrante G; Stefanini GG
    Lancet; 2020 May; 395(10235):1487-1495. PubMed ID: 32386592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
    Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
    JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
    O'Donoghue ML; Murphy SA; Sabatine MS
    Circulation; 2020 Aug; 142(6):538-545. PubMed ID: 32551860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
    Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
    Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.
    Valgimigli M; Gragnano F; Branca M; Franzone A; Baber U; Jang Y; Kimura T; Hahn JY; Zhao Q; Windecker S; Gibson CM; Kim BK; Watanabe H; Song YB; Zhu Y; Vranckx P; Mehta S; Hong SJ; Ando K; Gwon HC; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Jüni P; Mehran R
    BMJ; 2021 Jun; 373():n1332. PubMed ID: 34135011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2Y
    Gragnano F; Cao D; Pirondini L; Franzone A; Kim HS; von Scheidt M; Pettersen AR; Zhao Q; Woodward M; Chiarito M; McFadden EP; Park KW; Kastrati A; Seljeflot I; Zhu Y; Windecker S; Kang J; Schunkert H; Arnesen H; Bhatt DL; Steg PG; Calabrò P; Pocock S; Mehran R; Valgimigli M;
    J Am Coll Cardiol; 2023 Jul; 82(2):89-105. PubMed ID: 37407118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.
    Valgimigli M; Gragnano F; Branca M; Franzone A; da Costa BR; Baber U; Kimura T; Jang Y; Hahn JY; Zhao Q; Windecker S; Gibson CM; Watanabe H; Kim BK; Song YB; Zhu Y; Vranckx P; Mehta S; Ando K; Hong SJ; Gwon HC; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Calabrò P; Jüni P; Mehran R;
    JAMA Cardiol; 2024 May; 9(5):437-448. PubMed ID: 38506796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
    Liu F; Tantry US; Gurbel PA
    Expert Opin Pharmacother; 2015 Jun; 16(8):1149-65. PubMed ID: 25873127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
    Valentine N; Van de Laar FA; van Driel ML
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD005449. PubMed ID: 23152231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Monotherapy with a P2Y12 Inhibitor for Secondary Prevention in Patients with Established Atherosclerosis.
    Rodriguez JJ; Baron LE; Munoz OC; Diaz JJ
    Curr Cardiol Rep; 2022 Feb; 24(2):87-91. PubMed ID: 35028815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events.
    Bálint A; Tornyos D; El Alaoui El Abdallaoui O; Kupó P; Komócsi A
    Stroke; 2021 Aug; 52(9):2809-2816. PubMed ID: 34162232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of P2Y
    Casula M; Casu G; Talanas G; Spano A; Tantry U; Bilotta F; Micheluzzi V; Merella P; Porcheddu T; Gorog DA; Bonaca M; Jeong YH; Farkouh ME; Kubica J; Isgender M; Gurbel PA; Navarese EP
    Curr Probl Cardiol; 2024 Aug; 49(8):102635. PubMed ID: 38750991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
    Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
    Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
    Zhang Z; Chen O
    J Cardiovasc Pharmacol; 2021 May; 77(5):536-543. PubMed ID: 33760801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor.
    Sun MT; Huang S; Wiviott SD; Antman EM; Roe MT; Ohman EM; Neely M; Wallentin L; Wong CX
    Am J Cardiol; 2020 Apr; 125(8):1280-1283. PubMed ID: 32081368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis.
    Wu XT; He RR; Liang SZ; Ye GY; Ding SB
    Minerva Med; 2020 Apr; 111(2):173-180. PubMed ID: 32338843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
    Girotra S; Stebbins A; Wruck L; Marquis-Gravel G; Gupta K; Farrehi P; Benziger CP; Effron MB; Whittle J; Muñoz D; Kripalani S; Anderson RD; Jain SK; Polonsky TS; Ahmad FS; Roe MT; Rothman RL; Harrington RA; Hernandez AF; Jones WS
    J Am Heart Assoc; 2023 Oct; 12(20):e030385. PubMed ID: 37830344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention.
    Luo L; Fu M; Li Y; Chen Z; Yu J; Luo J; Hu S; Tu L; Xu X
    Clin Cardiol; 2020 Mar; 43(3):235-241. PubMed ID: 31777973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
    Wernly B; Rezar R; Gurbel P; Jung C
    J Thromb Thrombolysis; 2020 Jan; 49(1):173-176. PubMed ID: 31686298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.